Tandem Diabetes coverage initiated with equal-weight rating and $18 target price
TNDM•Barclays initiated coverage of Tandem Diabetes with an equal-weight rating and an $18 target price.
Related News
Werner Enterprises: Citigroup cuts target price to $37 from $43
WERN•
Barclays raises QIAGEN to overweight from equal-weight, lifts target price to $55 from $40
QGEN•
Gogoro appoints Peter Huang, Su-Ming Lin and Jason Chang to board, expands directors to seven
GGR•
Penguin Solutions jumps after raising FY revenue forecast as Q4 results beat
PENG•
J.P. Morgan Securities discloses 5.62% stake in Koh Young Technology
JPM•